About this program

Lirilumab (IPH2102/BMS-986015) is a fully human monoclonal antibody that is designed to block the interaction between KIR2DL-1,-2,-3 inhibitory receptors and their ligands.

Blocking these receptors facilitates activation of NK cells and, potentially some subsets of T cells, ultimately leading to destruction of tumor cells.

Lirilumab, an anti-KIR monoclonal antibody, aims at “unblinding” NK cells and facilitating their activation by blocking their inhibitory receptors.  

Lirilumab and related compounds blocking KIR receptors are licensed to Bristol-Myers Squibb Company (NYSE:BMY), for all indications.

Lirilumab has been or is currently being tested in several indications and combination settings.

Lirilumab continues to be well tolerated in monotherapy and in combination across multiple tumor indications in an exploratory clinical program with partner Bristol-Myers Squibb.

The assessment of efficacy from the ongoing exploration of doublet combinations, notably the nivolumab combination in an extended population of SCCHN patients, did not provide clear evidence of benefit to patients or an obvious development path.

Separately, full data of the EffiKIR Phase II study presented at ASH 2017 suggests that alternate dosing regimens could be worth exploring.

Discussions with Bristol-Myers Squibb regarding next steps are ongoing.

Documents: 

AttachmentSize
ASCO 2018: A pilot trial of lirilumab with or without azacytidine for patients with myelodysplastic syndrome249.32 KB
ASH 2017: Results of the Effikir trial (Phase 2 trial of lirilumab as maintenance treatment in elderly patients with AML)1.28 MB
ASH 2016: Phase IB/II Study of Lirilumab in Combination with Azacytidine (AZA) in Patients with Relapsed Acute Myeloid Leukemia384.97 KB
SITC 2016 : Late-breaking presentation on Interim Phase 1/2 Data for Lirilumab in Combination With Nivolumab1.58 MB
ESMO 2016: Safety of Lirilumab in Combination With Nivolumab or Ipilimumab in Two Phase 1 Studies in A/R Solid Tumors546.76 KB
ASCO 2015: A phase 1 dose-escalation study of lirilumab in patients with various hematologic or solid malignancies636.4 KB
ASH 2014: Lirilumab Enhances Anti-Tumor Efficacy of Elotuzumab236.48 KB
ASH 2014: Effects of IL-21, KIR Blockade, and CD137 Agonism on the Non-Clinical Activity of Elotuzumab1.62 MB
ASCO 2014 (BMS) : A Phase 1 Study of Lirilumab Administered in Combination With Nivolumab in Advanced Solid Tumors3.91 MB
ASH 2013: Repeated Dosing Of Anti-KIR (IPH2101) As Maintenance Therapy In Elderly Patients With Acute Myeloid Leukemia279.68 KB
ASH 2013: A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple Myeloma527.81 KB
ASH 2013: Anti-KIR antibody enhancement of anti-lymphoma activity of NK cells as monotherapy and in combination with anti-CD20401.35 KB
ASCO 2013: ALFA/GOELAMS Randomized Phase II Trial of Lirilumab as Maintenance Treatment in Elderly Patients with AML622.3 KB
ASCO 2013 (BMS): A Phase I Study of Lirilumab (BMS-986015), an Anti-KIR Monoclonal Antibody, Administered with Ipilimumab...2.59 MB
ASCO 2013 (BMS): A Phase I Dose-escalation and Cohort Expansion Study of Lirilumab Administered in Combination With Nivolumab1.88 MB
AACR 2013: Anti-tumoral efficacy of therapeutic human anti-KIR antibody (lirilumab) in a preclinical xenograft tumor model291.36 KB
ASH 2009: A Phase I Study of the Anti-Natural Killer Inhibitory Receptor (KIR) Monoclonal Antibody (IPH2101) in Elderly Patient61.11 KB